EMERYVILLE, Calif., March 28, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today has provided an on-demand webcast presentation from its CEO, Dr. Ron Najafi. The audio and slide presentation, recently presented at the Roth Capital Partners 23rd Annual Growth Stock Conference, is available at: http://www.wsw.com/webcast/roth24/nby/. The presentation will be available for 90 days.
